Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Cellular senescence as the causal nexus of aging
Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms [21] [20] GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations [18] [19] Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication [23] [24] Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations
RESEARCH BRIEFINGS A genetic basis for asymptomatic SARS-CoV-2 infection Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $32.99 / 30 days cancel any time Subscribe to this journal Receive 52 print issues and online access $199.00 per year only $3.83 per issue Rent or buy this article Prices vary by article type from$1.95 to$39.95 Prices may be subject to local taxes which are calculated during checkout doi: Figure 1 is published under a CC BY 4.0 licence
Some users feel tirzepatide is smoother, while others experience stronger digestive disruption
A total of 859 pediatric subjects received treatment with TAMIFLU for oral suspension either at a 2 mg per kg twice daily for 5 days or weight-band dosing
